Clinical trials: Arthritis, Rheumatoid
NSAID-induced Gastroduodenal Injury, Ulcers
Cobiprostone Prevention of NSAID-induced Gastroduodenal Injury
The primary purpose of this study is to determine the efficacy and safety of three dose levels of cobiprostone as compared to placebo in OA/RA patients treated with an NSAID for 20 months.
- Conditions
- NSAID-induced Gastroduodenal Injury, Ulcers, Rheumatoid Arthritis, Osteoarthritis
- Trial name
- NCT00597818
- Testing
- Cobiprostone, Non-steroidal anti-inflammatory drug
- Where
- 19 sites in United States
- Volunteers
- 121 people
- Sponsor
- Sucampo Pharma Americas, LLC
Rheumatoid Arthritis
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
In this open-label single arm study the safety and efficacy of Mabthera will be evaluated in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate.
- Trial name
- NCT01000610
- Testing
- rituximab [MabThera/Rituxan], methotrexate, methylprednisolone
- Where
- 4 sites in Tunisia
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
- Trial name
- ANTIBODY-RA (NCT01981473)
- Testing
- no intervention
- Where
- 54 sites in United States, Argentina and 3 more
- Volunteers
- 605 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients
The purpose of this study is to determine if the use of sub-cutaneous (SC) abatacept provides any structural benefit in patients with rheumatoid arthritis who have failed prior use of TNF therapy.
- Trial name
- NCT01351480
- Testing
- abatacept
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Arthritis & Rheumatic Disease Specialties Research
Arthritis, Rheumatoid
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid Arthritis
The purpose of this study is to determine the effectiveness and safety, over 6 months, of 5 doses of CP-690,550 for the treatment of adults with active rheumatoid arthritis. Five out of seven subjects will receive CP-690,550.
- Trial name
- NCT00550446
- Testing
- Adalimumab, CP-690-550, CP-690,550
- Where
- 63 sites in United States, Brazil and 13 more
- Volunteers
- 386 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
This is a multicenter, Phase II, randomized, double-blind, placebo-controlled, active comparator (Cohort 1 only), parallel-group, dose-ranging study to evaluate the efficacy and safety of GDC-0853 in participants with moderate to…
- Trial name
- NCT02833350
- Testing
- GDC-0853, Adalimumab, Folic Acid
- Where
- 150 sites in United States, Argentina and 9 more
- Volunteers
- 578 people
- Sponsor
- Genentech, Inc.
Arthritis, Rheumatoid
Study To Evaluate The Response To Enbrel And The Impact Of Rheumatoid Factor(RF) And Anti-Cyclic Citrullinated Peptide(Anti-CCP) In Rheumatoid Arthritis(RA) Patients
This study is to evaluate available local data in Iraqi patients with rheumatoid arthritis on Enbrel treatment with regards to the impact of Rheumatoid factor and Anti-cyclic citrullinated peptide using data from the Baghdad…
- Trial name
- NCT04428424
- Testing
- Enbrel
- Where
- Iraq
- Volunteers
- 1,493 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)
This Investigation is to be performed for the purpose of assessing the following information in the long-term post-marketing daily medical practice in the patients who receive REUMATOLEX 2 mg Capsule for the treatment of…
- Conditions
- Arthritis, Rheumatoid, High Dose
- Trial name
- NCT01414257
- Testing
- Methotrexate (MTX)
- Where
- Japan
- Volunteers
- 2,860 people
- Sponsor
- Pfizer
Persistence to Enbrel
Evaluate Effects of Personalized Patient Counselling for Enbrel® Therapy in Adults With Rheumatoid Arthritis
This study will evaluate whether the effect of personalized patient counselling tool, Information-Motivation-Strategy (IMS) based on the results of the Beliefs about Medicines Questionnaire (BMQ) will improve persistence of…
- Trial name
- NCT02346877
- Testing
- Personalized Patient Counselling
- Where
- 15 sites in Canada
- Volunteers
- 19 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
This study will evaluate the efficacy and safety of ocrelizumab, compared with placebo, in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to methotrexate.
- Trial name
- STAGE (NCT00406419)
- Testing
- Methotrexate, ocrelizumab
- Where
- United States
- Volunteers
- 1,015 people
- Sponsor
- Genentech, Inc.
Rheumatoid Arthritis
Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4
Olokizumab (OKZ) has been shown to reverse the inhibitory effect of IL-6 on the activity of Cytochrome P450 (CYP450) isozymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A4/5 in vitro.
- Trial name
- NCT04246762
- Testing
- Olokizumab, Omeprazole, Caffeine
- Where
- 2 sites in Bulgaria, Moldova
- Volunteers
- 17 people
- Sponsor
- R-Pharm International, LLC
Rheumatoid Arthritis
An Open Label Study for Participants With Rheumatoid Arthritis
The primary purpose of this study is to help answer if LY2127399 is safe and effective during long-term treatment in participants with Rheumatoid Arthritis.
- Trial name
- NCT01215942
- Testing
- LY2127399
- Where
- 327 sites in United States, Argentina and 25 more
- Volunteers
- 1,086 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis (RA)
A Study With Upadacitinib (ABT-494) in Subjects From China and Selected Countries With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs)
The study objectives of Period 1 of this study were to compare the efficacy, safety, and tolerability of upadacitinib versus placebo for the treatment of signs and symptoms of subjects from China and selected countries including…
- Trial name
- NCT02955212
- Testing
- Upadacitinib
- Where
- 43 sites in Brazil, China and 1 more
- Volunteers
- 338 people
- Sponsor
- AbbVie
Dry Eye
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
The study was planned to be conducted in 2 parts: Part 1 to determine the efficacy and safety of ECF843 vs vehicle, followed by Part 2 with additional exploratory assessments of ECF843 vs Vehicle.
- Trial name
- NCT04391894
- Testing
- ECF843, ECF843 vehicle
- Where
- 52 sites in United States
- Volunteers
- 718 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)
This is a study of the overall safety, tolerability, and pharmacokinetics (PK) of MK-8808 versus rituximab (MabThera® and Rituxan®) in participants with moderate to severe RA with an inadequate response or intolerance to…
- Trial name
- NCT01390441
- Testing
- MK-8808, MabThera® (rituximab), Methotrexate
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Sjogren's Syndrome
A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome
The present study will examine the role of circulating RNA complexed with autoantibodies and immune complexes and its role in activation of inflammatory pathways in patients with primary Sjogren's syndrome.
- Trial name
- RSLV-132 (NCT03247686)
- Testing
- RSLV-132
- Where
- 2 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- Resolve Therapeutics
Rheumatoid Arthritis
Long-term Treatment Study of Certolizumab Pegol (CDP870) as Add-on Medication to Methotrexate in Japanese Rheumatoid Arthritis (RA) Patients
The objectives of this study are to evaluate the safety and efficacy of certolizumab pegol as add-on medication to methotrexate over the long term in Japanese RA patients transferred from Study 275-08-001 (NCT00791999), and to…
- Trial name
- NCT00851318
- Testing
- Certolizumab pegol, Methotrexate
- Where
- 8 sites in Japan
- Volunteers
- 285 people
- Sponsor
- Astellas Pharma Inc
Rheumatoid Arthritis
Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American…
- Trial name
- FINCH 1 (NCT02889796)
- Testing
- Filgotinib, Adalimumab, MTX
- Where
- 230 sites in United States, Argentina and 28 more
- Volunteers
- 1,759 people
- Sponsor
- Gilead Sciences
Rheumatoid Arthritis
Acupressure in Rheumatoid Arthritis
The goal of this pilot trial is to better understand if acupressure is feasible and tolerable to people with rheumatoid arthritis.
- Trial name
- NCT05412121
- Testing
- Acupressure
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Michigan
Rheumatoid Arthritis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for inducing and sustaining clinical response in the treatment of Disease Modifying Antirheumatic Drug…
- Trial name
- C-early (NCT01519791)
- Testing
- Certolizumab Pegol, Methotrexate
- Where
- 178 sites in United States, Argentina and 20 more
- Volunteers
- 880 people
- Sponsor
- UCB Pharma SA